Return Of Two Classics

Today I am republishing one of my long lost classic essays, “Who Will Decide Which Pedigree Model You Will Invest In?“.  This essay was first published on November 15, 2010 but was removed from public view in December of that year.  Next week I will republish the second long lost essay, “Standards and Guidance For U.S. Pharma Supply Chain Technology“, originally published on November 22, 2010.  Both of these essay contain my thoughts on how the industry will eventually resolve the current confusion over which approach to ePedigree everyone in the U.S. supply chain should take.  Check them out and see if Continue reading Return Of Two Classics

Who Will Decide Which Pedigree Model You Will Invest In?

[This essay is one of two long lost essays that have now been restored on RxTrace.  It was originally published on November 15, 2010.  See “Return Of Two Classics” for an explanation.]

In one of my most widely read essays, “RFID is DEAD…At Unit-Level in Pharma”, I pointed out that the choice of serial number carrier technology to be used for compliance with the California Pedigree Law would be decided solely by the pharmaceutical manufacturers.  I pointed out that most of them would end up choosing 2D barcodes because their ongoing costs for Radio Frequency IDentification (RFID) would be too high.

Since the law doesn’t specify a carrier technology, and because the manufacturers will foot the bill for whatever technology is used, naturally, they get to lead the supply chain in that choice.  If you don’t like what they are choosing, then please, step up and pay them to put your preferred carrier technology on their packages.  I’m sure the manufacturer’s would put whatever you want to pay for on their packages as long as it would comply with the law.

But what about the pedigree model that the supply chain will use for compliance?  Can we apply similar logic to determine who will get to choose the technology that defines what a compliant pedigree is?  Yes we can!  And here it is. Continue reading Who Will Decide Which Pedigree Model You Will Invest In?

The Good News About Cancer Treatments

Photo by Tony Basa

I haven’t had cancer yet, but according to the American Cancer Society there is a 45% chance that I will contract some form of it before the end of my life.  The same goes for you if you are a male.  For women, the statistics aren’t quite so bad.  You have “only” a 38% chance of contracting cancer before the end of your life.

On the other hand, the Mayo Clinic encourages us to view these statistics very carefully.

“Just because studies have found that men have a nearly 50 percent chance of developing cancer in their lifetimes doesn’t mean that your risk, if you’re a man, is 50 percent. Your individual risk is based on many different factors, such as your age and habits, your family history of cancer, and the environment in which you live.”

Well said.  I would add that it also greatly depends on if you, or someone close to you, uses tobacco or not.  The point is, some of us have a much lower risk of developing cancer and others have a much higher risk than these averages indicate.

For many people, looking at their family history regarding cancer can be scary, but it is the first step Continue reading The Good News About Cancer Treatments

Announcing, Dirk Rodgers Consulting, LLC

After a month of intensive preparations I can now finally announce that I will leave my current employer on July 27, 2012, and on the following Monday I will open the books on Dirk Rodgers Consulting, LLC.  As many of you know, I have filled the role of Sr. Consultant in an full-time internal position at my employer for the last 3 1/2 years.  I will now be able to help clients navigate the same intersection between the pharmaceutical supply chain, track and trace technology, standards and regulatory compliance that I have written about for the last three years.

Over those three years I have been approached by a number of companies who were looking for quality help with their special problems in this realm but I was forced to turn them down or refer them to other consultants because I already had a full time job.  From now on I will be able to offer my own expertise instead.

I have pulled together a new website to market my services at www.DirkRodgers.com.  So far it is pretty minimal but through the fall I intend to expand the information it contains and establish more formal offerings.  If you know of someone in need of help with knowledge and strategy in the areas I write about, please refer them to either RxTrace.com or DirkRodgers.com.

SO NOW WHAT BECOMES OF RxTRACE?

The creation of Continue reading Announcing, Dirk Rodgers Consulting, LLC

Three Years of Heat and Light

I published my first essay on RxTrace three years ago on July 4, 2009 (see “Welcome to rxTrace”).  It took just two days after that first essay became visible on the internet before people were finding it through search engines and Google Alerts, a remarkable feature of self-publishing.  Since then I have published over a hundred essays on a wide range of topics exploring the intersection between the pharmaceutical supply chain, track and trace technology, standards and regulatory compliance.

This past year the number of people reading RxTrace regularly have more than doubled (see “The Abrupt Surge of Interest in Serialization and ePedigree Topics”).  That is a reflection of the steady march of time toward the effective dates of the California Pedigree law and other serialization mandates around the world, but it is also, I hope, a reflection of the type of writing about these subjects and perspectives that you can’t find anywhere else.

This year the most popular essay was “How Counterfeit Avastin Penetrated the U.S. Supply Chain”, which is the first essay to Continue reading Three Years of Heat and Light

Summer Writing

A fine summer vacation!

It’s summer and for whatever reason, readership tends to go down in the summer.  People are busy with vacations and vacation planning.  After work hours and weekends are dedicated to family and outdoor fun.  That’s the way it should be.

I do have some specific essays that I want to write this summer but I intend to be a little less regular until the end of August when I will return to my weekly publishing schedule.  I may also post one or two essays this summer that are not directly related to my normal subject matter.  Call it summer recreational thinking/writing.  Watch for those and let me know what you think about them.

There are a couple of big changes coming up Continue reading Summer Writing

PDUFA Will Not Include RxTEC

Politico.com reported today that the national track and trace addendum that many hoped would be made part of the Prescription Drug User Fee Act (PDUFA) of 2012 was rejected by the U.S. House and Senate Conference Committee.  That committee is working on merging the differences between the versions adopted by the two Houses of Congress into a single bill.  See “’Track And Trace’ On Ice For Now” in Politico PULSE.

According to Politico, “The word emerged late Sunday night from congressional staffers working on the package who said a last-minute compromise effort failed to win the support of stakeholders, and a decision had been made to drop it — for now.”

Assuming there isn’t a last minute reconsideration, this means that the odds are now slim that a national regulation will preempt the California pedigree law before its effective dates.  The remaining chance comes from the fact that the industry is well organized and well represented by the Pharmaceutical Distribution Security Alliance (PDSA) and could decide to back the introduction of a stand-alone bill that contains the essence of the Pharmaceutical Traceability Enhancement Code (RxTEC) language that was part of the PDUFA negotiations, or some other proposal.  The success of such an approach likely depends on Continue reading PDUFA Will Not Include RxTEC

Some People Actually WANT To Buy Counterfeit Drugs

It’s hard to imagine why people would actually prefer to buy drugs from internet websites that are obviously not licensed legitimate pharmacies.  That is, those that do not require proof of a valid prescription from a legitimate prescriber, and/or do not carry an online pharmacy certification (especially from the National Association of Boards of Pharmacy, NAPB, VIIPS program).  In an earlier essay I said this about people who would buy drugs from these illegitimate sources:

“Most of the criminal activity has moved out of the legitimate supply chain, mostly onto the internet.  You know, the internet, where criminals can sell drugs directly to the few consumers who are dumb enough to think that someone will sell them legitimate prescription drugs, but do so illegally by not requiring a prescription.  That is, they think that some faceless company would be willing to knowingly break one law, but could then be trusted to provide real pharmaceuticals at below market prices.  In the age of the internet, how do you protect people who are that gullible?”

A few weeks after writing that rather disparaging passage I met one of those gullible people Continue reading Some People Actually WANT To Buy Counterfeit Drugs

…a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance

DISCLAIMER: RxTrace contains some of the personal thoughts, ideas and opinions of RxTrace. The material contained in RxTrace is not legal advice. The writers of RxTrace are not lawyers.
The reader must make their own decisions about the accuracy of the opinions expressed in RxTrace. Readers are encouraged to consult their own legal counsel
and trading partners before taking any actions based on information found in RxTrace. RxTrace is not a vehicle for communicating
the positions of any company, organization or individual other than RxTrace.

RxTrace, a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance.
Contact Us | Privacy Statement
Copyright © 2009-2021 TrackTraceRx, Inc. All Rights Reserved.
RxTrace is a registered trademark of TrackTraceRx, Inc

SiteLock